Famotidine
FDA-approved product (tablet, oral), marketed as Famotidine, Famotidine Preservative Free, Famotidine Preservative Free (Pharmacy Bulk) and 7 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chest pain
- Duodenal ulcer
- Dyspepsia
- Esophagitis
- Gastric ulcer
- Gastroesophageal reflux disease
- Osteoarthritis
- Peptic ulcer
- Rheumatoid arthritis
- Ulcer disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- H2-receptor antagonists
- FDA pharmacologic class
- Histamine-2 Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Famotidine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
NCT01079052 · start 2007-11
Registered record
- Registry ID
- NCT01079052
- Conditions
- Healthy
- Interventions
- Famotidine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-11
- Completion
- 2007-12
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionFamotidinePhaseNot applicableRegistry statusCompletedEfficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
NCT00450216 · start 2007-03
Registered record
- Registry ID
- NCT00450216
- Conditions
- Ulcer
- Interventions
- Ibuprofen/famotidine; Ibuprofen
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2008-10
- Enrolment
- 906
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUlcerInterventionIbuprofen/famotidine; IbuprofenPhasePhase 3Registry statusCompletedUlcer Prevention Study in Post Gastric Bypass Patients
NCT00557349 · start 2006-11
Registered record
- Registry ID
- NCT00557349
- Conditions
- Marginal Ulcers
- Interventions
- Omeprazole; Famotidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2008-03
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMarginal UlcersInterventionOmeprazole; FamotidinePhasePhase 4Registry statusCompletedA Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)
NCT00945750 · start 2006-08
Registered record
- Registry ID
- NCT00945750
- Conditions
- Heartburn
- Interventions
- Famotidine FCT; Famotidine CT
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2006-09
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeartburnInterventionFamotidine FCT; Famotidine CTPhasePhase 1Registry statusCompletedBioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
NCT00802828 · start 2004-06
Registered record
- Registry ID
- NCT00802828
- Conditions
- Bioavailability
- Interventions
- Famotidine Tablets, 40 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-06
- Completion
- Not recorded
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBioavailabilityInterventionFamotidine Tablets, 40 mgPhasePhase 1Registry statusCompleted